Elan Pharma (United States)

Elan Pharmaceuticals, acquired by Perrigo, was a specialty pharmaceutical company focused on central nervous system and autoimmune disease treatments. Known for developing Tysabri (natalizumab) for multiple sclerosis and Crohn’s disease in partnership with Biogen. Elan’s drug delivery technologies and neurology expertise contributed to important advances in treating chronic neurological conditions.